Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Summary not available.
Veracyte (NASDAQ: VCYT) has announced significant leadership promotions aimed at enhancing its strategic vision in diagnostics. Tina Nova, Ph.D., is appointed president of the CLIA U.S. business, while Stephane Debono becomes general manager for IVD and EMEA organizations. Giulia C. Kennedy, Ph.D., is named global chief scientific officer and chief medical officer. These appointments are expected to align Veracyte's operations and bolster its market presence. The company focuses on developing innovative diagnostic tests to address unmet clinical needs, ultimately improving patient outcomes globally.
Veracyte, Inc. (NASDAQ: VCYT) released clinical data supporting the Envisia Genomic Classifier's role in enhancing diagnostic and treatment processes for patients with idiopathic pulmonary fibrosis (IPF). The findings, published in the Annals of the American Thoracic Society, demonstrate a significant increase in IPF diagnoses (39%) and physician confidence (36.2%) post-Envisia application. The study emphasizes reduced reliance on invasive procedures while promoting timely treatment recommendations, with potential benefits for approximately 200,000 patients annually in the U.S. and Europe.
Veracyte, Inc. (NASDAQ: VCYT) announced the Swedish Medical Technologies Product Council's recommendation for the Prosigna Breast Cancer Assay, enabling immediate reimbursement across all Swedish healthcare regions as of November 22, 2021. This marks a significant advancement following its prior approval in Germany, solidifying Prosigna's reimbursement momentum in the EU. The assay aids in chemotherapy decisions for women over 50 with specific breast cancer types, ensuring access without legal restrictions.
Veracyte (NASDAQ: VCYT) announced new data from three posters presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, showcasing the potential of Brightplex technology in immuno-oncology. This technology assesses the tumor micro-environment and aids in designing effective immunotherapies. Notably, findings from the PIONeeR project suggest that the Brightplex TCE assay can stratify non-small cell lung cancer patients into four subtypes, potentially predicting outcomes based on T-cell densities. This innovation positions Veracyte favorably in advancing cancer treatment.
Veracyte reported a 94% increase in total revenue to $60.4 million for Q3 2021, aided by its HalioDx acquisition. The company launched its innovative Percepta Nasal Swab and Decipher Bladder genomic tests amidst COVID-19 challenges. Despite growing revenues, Veracyte's operating expenses surged 123%, leading to a net loss of $14.1 million, a 243% increase year-over-year. The updated 2021 revenue guidance ranges from $210 million to $218 million, projecting 79% to 86% growth compared to 2020.
Veracyte (Nasdaq: VCYT) announced the inclusion of its Immunoscore Colon Cancer test in the new Pan-Asian ESMO Clinical Practice Guidelines for localized colon cancer diagnosis and treatment. The test, acquired through HalioDx in August 2021, assesses patient immune response and aids chemotherapy decisions for Stage II and III colon cancer patients. With increasing colorectal cancer cases in Asia, this recognition by Pan-Asian experts is a significant milestone, potentially facilitating wider reimbursement and patient access to the test.
Veracyte, Inc. (NASDAQ: VCYT) has published new data on its Afirma Genomic Sequencing Classifier (GSC) demonstrating its effectiveness in reducing unnecessary surgeries for patients with indeterminate thyroid nodules. The peer-reviewed study showed that Afirma GSC identified 30% more benign nodules compared to the original classifier, leading to a 41% reduction in surgeries compared to patients without molecular testing. The research reinforces the test's high sensitivity and specificity, indicating a shift in clinical practice for managing thyroid nodules.
Veracyte, Inc. (NASDAQ: VCYT) announced the presentation of three abstracts at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting from November 10-14, 2021. These abstracts focus on the company's Brightplex technology, acquired from HalioDx, which analyzes tumor micro-environments to enhance immunotherapy development. Corinne Danan, general manager of Biopharma, emphasized the importance of this technology in understanding therapeutic mechanisms. Veracyte aims to improve cancer treatment through innovative diagnostic solutions that speed up patient care.
Veracyte (NASDAQ: VCYT) presented new data at the ASTRO Annual Meeting 2021, indicating that its Decipher Prostate genomic classifier is effective in tailoring treatment for men with prostate cancer after radical prostatectomy. Results from a phase 3 trial involving 226 patients showed that those classified as high-risk using the Decipher tool had over double the likelihood of experiencing cancer progression with radiotherapy alone. This study highlights the potential for personalized treatment plans, enhancing outcomes for patients with rising PSA levels.